Namenstra Tablets / Film-coated

Memantine Hydrochloride

10mg

Lifepharma FZE

Pack size	28's (14's Blister x 2)
Dispensing mode	POM
Source	UAE
Agent	LIFEPharma FZE
Retail Price	143.00 AED

Available as:

10mg - Tablets / Film-coated 5mg - Tablets / Film-coated

Indications

Namenstra Tablets / Film-coated is used for: Alzheimer's dementia.

Adult Dose

Oral Moderate to severe dementia in Alzheimer's disease Adult: As hydrochloride: Initially, 5 mg daily in the morning for the 1st wk; increase dose wkly in steps of 5 mg. Max: 20 mg daily. Wait for at least 1 wk between dose changes. Doses >10 mg/day should be given in 2 divided doses. Suggested titration: 5 mg daily for >1 wk; 5 mg bid for >1 wk; 15 mg daily given in 5- and 10-mg separated doses for >1 wk; then 10 mg bid. Hepatic impairment Mild or moderate (Child Pugh A/B): No dosage adjustment required Severe (Child Pugh C): Caution

Child Dose

Renal Dose

Renal impairment: CrCl (ml/min) Dosage Recommendation 5-29 Max: 10 mg daily. 30-49 10 mg daily (after initial dose of 5 mg daily), if well tolerated for at least 7 days, may increase to 20 mg daily.

Administration

May be taken with or without food.

Contra Indications

Hypersensitivity to memantine or components of the formulation. Severe renal impairment.

Precautions

Renal impairment; epilepsy. Pregnancy and lactation. Closely monitor patients with recent MI, uncompensated CHF, uncontrolled hypertension. Predisposition to convulsions; conditions that increase urinary pH. Lactation: Unknown whether drug is excreted into breast milk; use with caution

Pregnancy-Lactation

Pregnancy There are no adequate data on developmental risk associated with use; adverse developmental effects (decreased body weight, and skeletal ossification) observed in offspring of rats during pregnancy at doses associated with minimal maternal toxicity; doses are higher than used in humans at maximum recommended daily dose Animal data Oral administration to rats during period of organogenesis resulted in decreased skeletal ossification in fetuses at highest dose tested; the higher no-effect dose (6 mg/kg/day) was approximately 3 times MRHD on a mg/m² basis Oral administration of memantine to rabbits during period of organogenesis resulted in no adverse developmental effects; highest dose tested was approximately 30 times the MRHD on a mg/m² basis Oral administration to rats from late gestation throughout lactation to weaning, resulted in decreased pup weights at highest dose tested; the higher no-effect dose (6 mg/kg/day) is approximately 3 times the MRHD on a mg/ m² basis Lactation There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production Developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal condition

Interactions

May increase effects of antimuscarinics and dopaminergics. May reduce effects of antipsychotics and barbiturates. May alter effects of dantrolene, baclofen. Reduced clearance with carbonic anhydrase inhibitors and sodium bicarbonate. Potentially Fatal: Increased risk of adverse effects with amantadine, dextromethorphan or ketamine.

Adverse Effects

Side effects of Memantine Hydrochloride : 1-10% Dizziness (7%), Confusion (6%), Headache (6%), Constipation (5%), Cough (4%), Hypertension (4%), Backache (3%), Pain (3%), Somnolence (3%), Syncope (3%), Vomiting (3%), Dyspnea (2%), Fatigue (2%) <1% Acute renal failure, Cerebral infarction, Cerebrovascular accident, Deep venous thrombosis, Hepatitis, liver failure, Intracranial hemorrhage, Neuroleptic malignant syndrome, Seizure (including grand mal), Stevens-Johnson syndrome, Transient ischemic attack

Mechanism of Action

Memantine, a derivative of amantadine, is a noncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist. It affects transmission of glutamate, the primary excitatory neurotransmitter in the CNS. Glutamate may contribute to the pathogenesis of Alzheimer's disease by overstimulating various glutamate receptors resulting in excitotoxicity and neuronal cell death.

Note

Namenstra 10mg Tablets / Film-coated manufactured by Lifepharma FZE. Its generic name is Memantine Hydrochloride. Namenstra is availble in United Arab Emirates. Farmaco UAE drug index information on Namenstra Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Memantine Hydrochloride :

Tablets / Film-coated

Zementa ^10mg

SPIMACO (Al Qassim Pharmaceutical Plant)

Tablets / Film-coated

Memaxia ^{10 mg}

Jamjoom Pharmaceuticals Company Ltd.

Tablets

Ebixa ^10mg

H. Lundbeck A/S

Tablets / Film-coated

Ebixa ^20mg

H. Lundbeck A/S

Solution (Oral)

Ebixa 5mg/Pump Actuation ^{10mg/ml 10mg/ml (equiv. to 8.32mg memantine)}

H. Lundbeck A/S